Tipping Point: Tariffs Create Uncertainty, Risk Long-Term Price Increases, Shortages

President Trump’s 10% tariff on active pharmaceutical ingredients and finished dosage forms could push some generic drug makers to exit therapeutic categories if they cannot absorb the new costs, which could lead to shortages.